CA74285/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2000	2
2002	1
2003	4
2004	3
2005	1
2006	3
2007	2
2008	1
2009	3
2012	1
2013	1
2024	0

1

Targeting insulin-like growth factor pathways.

Yee D. Yee D. Br J Cancer. 2006 Feb 27;94(4):465-8. doi: 10.1038/sj.bjc.6602963. Br J Cancer. 2006. PMID: 16450000 Free PMC article. Review.

2

Disrupting insulin-like growth factor signaling as a potential cancer therapy.

Sachdev D, Yee D. Sachdev D, et al. Mol Cancer Ther. 2007 Jan;6(1):1-12. doi: 10.1158/1535-7163.MCT-06-0080. Mol Cancer Ther. 2007. PMID: 17237261 Review.

3

Insulin-like growth factors and breast cancer therapy.

Zeng X, Yee D. Zeng X, et al. Adv Exp Med Biol. 2007;608:101-12. doi: 10.1007/978-0-387-74039-3_7. Adv Exp Med Biol. 2007. PMID: 17993235 Review.

4

Insulin-like growth factor-I and cancer risk.

Ibrahim YH, Yee D. Ibrahim YH, et al. Growth Horm IGF Res. 2004 Aug;14(4):261-9. doi: 10.1016/j.ghir.2004.01.005. Growth Horm IGF Res. 2004. PMID: 15231294 Review.

5

Crosstalk between the insulin-like growth factors and estrogens in breast cancer.

Yee D, Lee AV. Yee D, et al. J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):107-15. doi: 10.1023/a:1009575518338. J Mammary Gland Biol Neoplasia. 2000. PMID: 10791773 Review.

6

Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.

Zhang X, Diaz MR, Yee D. Zhang X, et al. Breast Cancer Res Treat. 2013 Jun;139(2):351-60. doi: 10.1007/s10549-013-2541-y. Epub 2013 May 18. Breast Cancer Res Treat. 2013. PMID: 23686416 Free PMC article.

7

Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells.

Jackson JG, Kreisberg JI, Koterba AP, Yee D, Brattain MG. Jackson JG, et al. Oncogene. 2000 Sep 21;19(40):4574-81. doi: 10.1038/sj.onc.1203825. Oncogene. 2000. PMID: 11030146

8

The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance.

Gross JM, Yee D. Gross JM, et al. Cancer Metastasis Rev. 2003 Dec;22(4):327-36. doi: 10.1023/a:1023720928680. Cancer Metastasis Rev. 2003. PMID: 12884909 Review.

9

Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.

Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Byron SA, et al. Br J Cancer. 2006 Nov 6;95(9):1220-8. doi: 10.1038/sj.bjc.6603354. Epub 2006 Oct 17. Br J Cancer. 2006. PMID: 17043687 Free PMC article.

10

Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.

Fagan DH, Uselman RR, Sachdev D, Yee D. Fagan DH, et al. Cancer Res. 2012 Jul 1;72(13):3372-80. doi: 10.1158/0008-5472.CAN-12-0684. Epub 2012 May 9. Cancer Res. 2012. PMID: 22573715 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year